EWTX
Edgewise Therapeutics Inc
39.20$
-0.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
Edgewise Therapeutics Inc (EWTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -44 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.7 | -4.0 | -3.3 | -4.6 | -6.1 | -9.8 | -8.3 | -9.4 | -13 | -16 | -12 | -12 | -23 | -20 | -22 | -27 | -29 | -26 | -27 | -27 | -38 | -33 | -35 | -39 | -43 | -44 | -159 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 2.3 | |
| 0.0 | 0.0 | 0.1 | 0.2 | 0.3 | 0.7 | 1.5 | 1.9 | 2.0 | 2.0 | 3.2 | 3.7 | 3.8 | 4.0 | 4.6 | 5.2 | 4.9 | 5.2 | 6.9 | 7.7 | 9.1 | 7.7 | 8.1 | -25 | 8.7 | 9.4 | 1.3 | |
| 0.0 | 0.0 | 0.1 | – | 0.3 | 0.7 | 1.5 | 1.9 | 2.0 | 2.0 | 3.2 | 3.7 | 3.8 | 4.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.4 | -0.1 | 0.3 | 1.5 | 0.4 | -0.2 | 3.1 | 1.3 | -0.7 | -2.8 | 2.0 | 5.5 | -2.0 | -0.3 | 1.0 | -0.2 | -2.3 | 3.2 | 2.5 | 6.9 | -4.8 | -2.6 | -0.7 | 2.7 | -1.8 | 0.8 | 0.9 | |
| 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.1 | 0.5 | 0.1 | 0.4 | 0.6 | 1.3 | 3.3 | 4.4 | 0.8 | 0.5 | 0.2 | 0.3 | 0.2 | 0.5 | 0.3 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.0 | 0.6 | |
| 0.0 | -0.2 | 0.0 | -24 | -65 | -160 | -32 | 14 | 31 | 0.0 | -26 | -76 | 49 | 3.4 | 23 | 27 | -268 | 37 | 25 | 21 | 44 | -162 | 36 | 50 | 2.4 | 78 | 166 | |
| – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 187 | -0.9 | 0.0 | 0.3 | 0.1 | 0.4 | 130 | 0.0 | 0.0 | 0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 0.0 | 0.0 | -0.3 | 0.0 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 187 | 0.1 | 25 | 95 | 187 | -0.9 | 0.0 | 0.3 | 0.1 | 0.2 | 130 | -0.3 | 0.0 | 0.4 | -0.2 | 53 | 241 | 2.0 | 3.3 | 2.9 | 2.2 | 188 | 1.7 | 4.0 | 12 | -9.1 | 8.7 | |
| -2.7 | -4.0 | 22 | 66 | 116 | -171 | -40 | 5.0 | 19 | -16 | 91 | -88 | 26 | -16 | 1.2 | 53 | -56 | 13 | 1.3 | -3.1 | 8.3 | -6.5 | 2.6 | 15 | -28 | 26 | 16 | |
| -2.7 | -4.2 | -3.3 | -4.6 | -6.1 | -9.8 | -8.7 | -9.5 | -13 | -17 | -13 | -15 | -27 | -21 | -23 | -27 | -29 | -26 | -28 | -27 | -38 | -33 | -35 | -38 | -43 | -44 | -160 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.